Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Veroni, Caterina ^a   Marnetto, Fabiana ^b   Granieri, Letizia ^b   Bertolotto, Antonio ^b   Ballerini, Clara ^c   Repice, Anna Maria ^d   Schirru, Lucia ^e   Coghe, Giancarlo ^e   Cocco, Eleonora ^e   Anastasiadou, Eleni ^f,g   Puopolo, Maria ^a   Aloisi, Francesca ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Epstein Barr virus; Gene expression; Immune response; Multiple sclerosis; Multivariate analysis

Indexed keywords

COMPLEMENTARY DNA; HLA ANTIGEN CLASS 2;

ACCURACY; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; HUMAN; IMMUNE GENE; IMMUNOREGULATION; INNATE IMMUNITY; MALE; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ACTIVATION; VIRUS GENE; VIRUS LATENCY; YOUNG ADULT; BLOOD; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; REPRODUCIBILITY;

ADULT; AGED; CEREBROSPINAL FLUID; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84937028088     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0353-1     Document Type: Article

References (74)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-17. doi: 10.1016/S0140-6736(08)61620-7 .
2. Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122:15-58. doi: 10.1016/B978-0-444-52001-2.00002-9 .
3. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13:518-24. doi: 10.1016/j.autrev.2014.01.012 .
4. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180-8. doi: 10.1172/JCI58649 .
5. Hauser SL. The Charcot Lecture|beating MS: a story of B cells, with twists and turns. Mult Scler. 2015;21:8-21. doi: 10.1177/1352458514561911 .
6. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci. 2008;274:39-41. doi: 10.1016/j.jns.2008.03.022 .
7. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16:528-36. doi: 10.1111/j.1468-1331.2009.02532.x .
8. McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013;73:1463-81. doi: 10.1007/s40265-013-0102-7 .
9. Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, Hernis A, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult Scler. 2014;20:1900-3. doi: 10.1177/1352458514538111 .
10. Buck D, Hemmer B. Biomarkers of treatment response in multiple sclerosis. Expert Rev Neurother. 2014;14:165-72. doi: 10.1586/14737175.2014.874289 .
11. Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267-76. doi: 10.1038/nrneurol.2013.41 .
12. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18:552-6. doi: 10.1177/1352458512443092 .
13. Modvig S, Degn M, Roed H, Sørensen T, Larsson H, Langkilde A, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015.
14. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138:918-31. doi: 10.1093/brain/awv017 .
15. Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 2003;12:2191-9.
16. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol. 2004;55:410-7.
17. Brynedal B, Khademi M, Wallström E, Hillert J, Olsson T, Duvefelt K. Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis. 2010;37:613-21. doi: 10.1016/j.nbd.2009.11.014 .
18. Lindsey JW, Agarwal SK, Tan FK. Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells. Mol Med. 2011;17:95-102. doi: 10.2119/molmed.2010.00071 .
19. Ratzer R, Søndergaard HB, Christensen JR, Börnsen L, Borup R, Sørensen PS, et al. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Mult Scler. 2013;19:1841-8. doi: 10.1177/1352458513500553 .
20. Nickles D, Chen HP, Li MM, Khankhanian P, Madireddy L, Caillier SJ, et al. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet. 2013;22:4194-205. doi: 10.1093/hmg/ddt267 .
21. Kemppinen AK, Kaprio J, Palotie A, Saarela J. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open. 2011;1(1):e000053. doi: 10.1136/bmjopen-2011-000053 .
22. Monteyne P, Sindic CJ. Data on cytokine mRNA expression in CSF and peripheral blood mononuclear cells from MS patients as detected by PCR. Mult Scler. 1998;4:143-6.
23. Romme Christensen J, Börnsen L, Hesse D, Krakauer M, Sørensen PS, Søndergaard HB, et al. Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2012;9:215. doi: 10.1186/1742-2094-9-215 .
24. Jernås M, Malmeström C, Axelsson M, Olsson C, Nookaew I, Wadenvik H, et al. MS risk genes are transcriptionally regulated in CSF leukocytes at relapse. Mult Scler. 2013;19:403-10. doi: 10.1177/1352458512455466 .
25. Noutsias M, Rohde M, Block A, Klippert K, Lettau O, Blunert K, et al. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol. 2008;9:3. doi: 10.1186/1471-2199-9-3 .
26. Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol. 2010;5:271-7. doi: 10.1007/s11481-010-9201-3 .
27. Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunol. 2014;3(10):e27. doi: 10.1038/cti.2014.25 .
28. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol. 2009;22:201-6. doi: 10.1097/WCO.0b013e32832b4c8d .
29. Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Viruses. 2012;4:3701-30.
30. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899-912.
31. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012;78:15-23. doi: 10.1212/WNL.0b013e31823ed057 .
32. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM, NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna. Austria Brain. 2011;134:2772-27.
33. Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010;40:878-87. doi: 10.1002/eji.200939761 .
34. Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9:e1003220. doi: 10.1371/journal.ppat.1003220 .
35. Lossius A, Johansen JN, Vartdal F, Robins H, Jüratē Šaltytē B, Holmøy T, et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol. 2014;44:3439-52. doi: 10.1002/eji.201444662 .
36. van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler. 2015. [Epub ahead of print]
37. Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006;129:1493-506.
38. Lindsey JW, Hatfield LM, Crawford MP, Patel S. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult Scler. 2009;15:153-8. doi: 10.1177/1352458508097920 .
39. Franciotta D, Bestetti A, Sala S, Perucca P, Jarius S, Price RW, et al. Broad screening for human herpesviridae DNA in multiple sclerosis cerebrospinal fluid and serum. Acta Neurol Belg. 2009;109:277-82.
40. Cocuzza CE, Piazza F, Musumeci R, Oggioni D, Andreoni S, Gardinetti M, et al. Quantitative detection of Epstein-Barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis. PLoS One. 2014;9(4):e94497. doi: 10.1371/journal.pone.0094497 .
41. Ferrante P, Omodeo-Zorini E, Zuffolato MR, Mancuso R, Caldarelli-Stefano R, Puricelli S, et al. Human T-cell lymphotropic virus tax and Epstein-Barr virus DNA in peripheral blood of multiple sclerosis patients during acute attack. Acta Neurol Scand Suppl. 1997;169:79-85.
42. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000;55:178-84.
43. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75-82.
44. Irizar H, Muñoz-Culla M, Sepúlveda L, Sáenz-Cuesta M, Prada Á, Castillo-Triviño T, et al. Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression. PLoS One. 2014;9(2):e90482. doi: 10.1371/journal.pone.0090482 .
45. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol. 2005;58:840-6.
46. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302. doi: 10.1002/ana.22366 .
47. Filippi M, Rocca MA, Bastianello S, Comi G, Gallo P, Gallucci M, et al. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurol Sci. 2013;34:2085-93. doi: 10.1007/s10072-013-1485-7 .
48. Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 2014;83:1210-6. doi: 10.1212/WNL.0000000000000809 .
49. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128:1667-76.
50. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200-11.
51. Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One. 2008;3:e2559. doi: 10.1371/journal.pone.0002559 .
52. Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73:2003-10. doi: 10.1212/WNL.0b013e3181c5b457 .
53. Longhini AL, von Glehn F, Brandão CO, de Paula RF, Pradella F, Moraes AS, et al. Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse. J Neuroinflammation. 2011;8(1):2. doi: 10.1186/1742-2094-8-2 .
54. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One. 2012;7(11):e48370. doi: 10.1371/journal.pone.0048370 .
55. Han S, Lin YC, Wu T, Salgado AD, Mexhitaj I, Wuest SC, et al. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol. 2014;192:2551-63. doi: 10.4049/jimmunol.1302884 .
56. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17:1700-9.
57. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9:405-11.
58. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3:801-12.
59. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79:1296-307.
60. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009;132:3353-65. doi: 10.1093/brain/awp228. Epub .
61. Bustamante MF, Nurtdinov RN, Río J, Montalban X, Comabella M. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. PLoS One. 2013;8(4):e60994. doi: 10.1371/journal.pone.0060994 .
62. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008;3(4):e1927. doi: 10.1371/journal.pone.0001927 .
63. Verweij CL, Vosslamber S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med. 2013;15:51-60.
64. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003;41:5419-28.
65. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol. 2005;174:6599-607.
66. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010;67:159-69. doi: 10.1002/ana.21886 .
67. Fraser KB, Haire M, Millar JHD, McCrea. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet. 1979;ii:715-7.
68. Tørring C, Andreasen C, Gehr N, Bjerg L, Petersen T, Höllsberg P. Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis. Acta Neurol Scand. 2014;130:90-6. doi: 10.1111/ane.12249 .
69. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol. 2013;3:227-32. doi: 10.1016/j.coviro.2013.04.005 .
70. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. Review.
71. Serafini B, Rosicarelli B, Aloisi F, Stigliano E. Epstein-Barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2014;73:729-31. doi: 10.1097/NEN.0000000000000082 .
72. Münz C. Role of human natural killer cells during Epstein-Barr virus infection. Crit Rev Immunol. 2014;34:501-7.
73. Dreyfus DH. Autoimmune disease: a role for new anti-viral therapies? Autoimmun Rev. 2011;11:88-97. doi: 10.1016/j.autrev.2011.08.005 .
74. Annibali V, Mechelli R, Romano S, Buscarinu MC, Fornasiero A, Umeton R, et al. IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev. 2014. doi: 10.1016/j.cytogfr.2014.10.010 .